New Pharmac drugs will 'significantly' impact quality of life for cancer patients - PM
New drugs for lung cancer and breast cancer, as well as a new treatment for multiple sclerosis will be funded by Pharmac, the Government announced today. In addition, access to a treatment for respiratory disease - pirfenidone, known by brand name Esbriet - will be widened. The drugs for non-small cell lung cancer and HER-2 positive metastatic breast cancer will be available from December 1. Health Minister David Clark said the drug funding would help 420 people, "including people living with advanced cancer". "Pharmac is currently consulting on three more cancer drugs - olaparib (Lynparza) for ovarian cancer, fulvestrant (Faslodex) for breast cancer and venetoclax (Venclexta) for chronic lymphocytic leukaemia," he said in a statement. The drugs funded from December 1 will be alectinib, known as Alecensa, for ALK positive advanced non-small cell lung cancer and trastuzumab emtansine, which goes by brand name Kadcyla, for HER-2 positive metastatic breast cancer.
"It will take time to modernise our approach to cancer care and control and improve survival rates, but today signifies good progress on the delivery of our plan," Mr Clark said.
==========================================================
Elvis in the Park
Elvis in the Park. 11th January from 11am till 5pm. Cranwell Park in Henderson. Free Family day out. Check out the Classic Cars and Hot Rods. Bring your chairs, sun tan lotion, water, and your smile. We are celebrating Elvis' 91st Birthday. Any questions ph Jackie 0274901126. Park at Tui Glen as easy walk over bridge to Cranwell Park
Today’s Mind-Bender is the Last of the Year! Can You Guess It Before Everyone Else? 🌟🎁🌲
I dance in the sky with green and gold, a spectacle few are lucky to behold; I’m best seen in the south, a celestial sight—what am I, lighting up the New Zealand night?
Do you think you know the answer? Simply 'Like' this post and we'll post the answer in the comments below at 2pm on the day!
Want to stop seeing these in your newsfeed? No worries! Simply head here and click once on the Following button.
Loading…